WO2021027566A1 - 氧氮杂卓类化合物的制备方法 - Google Patents
氧氮杂卓类化合物的制备方法 Download PDFInfo
- Publication number
- WO2021027566A1 WO2021027566A1 PCT/CN2020/105248 CN2020105248W WO2021027566A1 WO 2021027566 A1 WO2021027566 A1 WO 2021027566A1 CN 2020105248 W CN2020105248 W CN 2020105248W WO 2021027566 A1 WO2021027566 A1 WO 2021027566A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylamino
- alkyl
- compound
- alkoxy
- reaction
- Prior art date
Links
- 0 *C1N=Cc2cc(*)c(*)cc2OC1 Chemical compound *C1N=Cc2cc(*)c(*)cc2OC1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the invention relates to a method for preparing oxazepine compounds.
- Hepatitis B virus referred to as hepatitis B
- HBV hepatitis B virus
- Hepatitis B virus is a hepatotropic virus that mainly exists in liver cells and damages liver cells, causing inflammation, necrosis, and fibrosis of liver cells.
- Acute hepatitis B in most adults can heal itself through its own immune mechanism.
- chronic hepatitis B (CHB) has become a great challenge for global health care, and it is also the main cause of chronic liver disease, cirrhosis and liver cancer (HCC).
- HBsAg hepatitis B virus surface antigen
- Patent application WO2018214875 found that a surface antigen inhibitor can effectively reduce HBsAg.
- the anti-HBV drugs currently approved for marketing are mainly immunomodulators (interferon- ⁇ and peginterferon- ⁇ -2 ⁇ ) and antiviral drugs (lamivudine, adefovir dipivoxil, entecavir, Bivudine, Tenofovir, Kravudine, etc.).
- antiviral therapy drugs are nucleotide drugs, and their mechanism of action is to inhibit the synthesis of HBV DNA, and cannot directly reduce HBsAg levels.
- nucleotide drugs show that the clearance rate of HBsAg is similar to that of natural observation (Janssen et al.
- the present invention provides a method for preparing the compound of formula (I),
- W is selected from OH, C 1-6 alkoxy and C 1-6 alkylamino
- R 1 is selected from C 1-6 alkyl
- R 3 is selected from
- n is selected from 0, 1, 2, 3, 4 and 5;
- R a and R b are independently selected from COOH, F, Cl, Br, I, OH, CN, NH 2 , CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , OCH 3 , -NHCH 3 ,- N(CH 3 ) 2 and CF 3 .
- the above-mentioned R is selected from H, OH, CN, NH 2 ,
- the aforementioned W is selected from OH, -OCH 2 CH 3 and -N(CH 3 ) 2 .
- R 1 is selected from
- R 2 is selected from Cl, Br, CN, CH 3 ,
- R 3 is selected from
- the above preparation method includes the following steps:
- R 1 , R 2 and R 3 are as defined in the present invention.
- the above preparation method includes the following steps:
- R 1 is as defined in the present invention.
- the above preparation method includes the following steps:
- R 1 is as defined in the present invention.
- the above preparation method includes the following steps:
- R 1 , R 2 and R 3 are as defined in the present invention.
- the reproducibility of the reaction is poor, and the yield is low, and the yield of compound 3 in the pharmaceutical synthesis process is only about 7%.
- the synthesis conditions of compound B-1 used for ring closure are harsh and purification is difficult, and the purity of compound B-1 cannot be controlled, resulting in low yield and poor repeatability of the subsequent ring closure reaction.
- the reagents are easy to prepare, economical and environmentally friendly, and the quality is controllable, and the yield is greatly improved (80%) after the compound B is used, and the reaction is stable and can be scaled up.
- compound (II) and compound (A) undergo alkylation reaction to obtain compound III.
- the present invention has been optimized and screened through process optimization and selected to use isobutyl chloroformate to react with carboxylic acid to generate active ester, and then use mild sodium borohydride reducing agent to reduce carboxylic acid to obtain the required
- the hydroxyl group can scale up the production of compound A-3 stably and safely.
- There are many ways to reduce carboxylic acid to hydroxyl You can use lithium tetrahydroaluminum to directly reduce it, or you can use borane tetrahydrofuran solution to directly reduce it, or use a milder reducing agent such as lithium borohydride and boron after esterification of the carboxylic acid. Reduction with reducing agents such as sodium hydride and potassium borohydride.
- Sodium borohydride is cheaper than lithium aluminum tetrahydrogen.
- Sodium borohydride is chemically more active than tetrahydroaluminum lithium and tetrahydroaluminum lithium. It is very easy to ignite spontaneously when exposed to water or humid air, which poses great safety risks and is not conducive to scale-up production.
- Sodium borohydride is reduced compared to lithium aluminum tetrahydrogen, and the active ester prepared by it is stable. Sodium borohydride is added at about 0°C, the reaction temperature is appropriate, and the energy consumption of scale-up production is low.
- the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by substituents, and can include deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable of.
- oxygen it means that two hydrogen atoms are replaced. Oxygen substitution will not occur on aromatic groups.
- optionally substituted means that it can be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
- any variable such as R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, and R has independent options in each case.
- combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- the number of atoms in a ring is generally defined as the number of ring members.
- “5-7 membered ring” refers to a “ring” in which 5-7 atoms are arranged around.
- C 1-6 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 6 carbon atoms.
- the C 1-6 alkyl includes C 1-5, C 1-4, C 1-3 , C 1-2, C 2-6, C 2- 4, C 6 and C 5 alkyl groups like; which may Is monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
- C 1-6 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, etc.
- C 1-3 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine) .
- Examples of C 1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- C 1-6 alkoxy refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an oxygen atom.
- the C 1-6 alkoxy group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 and C 3 alkoxy etc. .
- C 1-6 alkoxy examples include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy) Oxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
- C 1-3 alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an oxygen atom.
- the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy groups and the like.
- Examples of C 1-3 alkoxy include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy) and the like.
- C 1-6 alkylamino refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-6 alkyl groups include C 1-4, C 1-3, C 1- 2, C 2-6, C 2-4, C 6, C 5, C 4, C 3 and C 2 alkylamino Wait.
- C 1-6 alkylamino examples include, but are not limited to -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -N(CH 2 CH 3 )( CH 2 CH 3 ), -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 , -NHCH 2 CH 2 CH 2 CH 3 and so on.
- C 1-3 alkylamino means those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-3 alkylamino group includes C 1-2 , C 3 and C 2 alkylamino groups and the like.
- Examples of C 1-3 alkylamino groups include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 ,- NHCH 2 (CH 3 ) 2 and so on.
- C 1-6 alkylthio refers to those alkyl groups containing 1 to 6 carbon atoms that are attached to the rest of the molecule through a sulfur atom.
- the C 1-6 alkylthio group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkane Sulfur-based etc.
- Examples of C 1-6 alkylthio include, but are not limited to, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 (CH 3 ) 2 and the like.
- C 1-3 alkylthio refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through a sulfur atom.
- the C 1-3 alkylthio group includes C 1-3 , C 1-2 and C 3 alkylthio groups and the like.
- Examples of C 1-3 alkylthio include, but are not limited to, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 (CH 3 ) 2 and the like.
- heteroalkenyl by itself or in combination with another term means a stable linear or branched alkenyl radical or combination thereof consisting of a certain number of carbon atoms and at least one heteroatom or heteroatom group Things.
- the heteroatoms are selected from B, O, N, and S, where nitrogen and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized.
- the heteroalkenyl is a C 2-5 heteroalkenyl; in other embodiments, the heteroalkenyl is a C 2-3 heteroalkenyl.
- heteroatom or heteroatom group can be located at any internal position of the heteroalkenyl group, including the position where the alkenyl group is attached to the rest of the molecule, but the terms "alkenyloxy”, “alkenylamino” and “alkenylthio” are customary The expression refers to those alkenyl groups attached to the rest of the molecule through an oxygen atom, an amino group, or a sulfur atom, respectively.
- C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 6 carbon atoms, which is a monocyclic and bicyclic ring system.
- the C 3-6 cycloalkyl includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
- Examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- the term "3-8 membered heterocycloalkyl" by itself or in combination with other terms means a saturated cyclic group consisting of 3 to 8 ring atoms, with 1, 2, 3 or 4 ring atoms Are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2). It includes monocyclic and bicyclic ring systems, where the bicyclic ring system includes spiro, fused, and bridged rings.
- a heteroatom may occupy the position of attachment of the heterocycloalkyl to the rest of the molecule.
- the 3-8 membered heterocycloalkyl group includes 3-6 membered, 3-5 membered, 4-6 membered, 5-6 membered, 4-membered, 5-membered and 6-membered heterocycloalkyl group.
- 3-8 membered heterocycloalkyl examples include, but are not limited to, azetidinyl, oxetanyl, thietane, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- Piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), Dioxanyl, dithiazyl, isoxazolidinyl, isothiazolidinyl
- DCM dichloromethane
- EtOH stands for ethanol
- DME ethylene glycol dimethyl ether
- MeCN stands for acetonitrile
- Bn stands for benzyl
- Boc stands for tert-butyl carbonyl is an amine protecting group
- Boc 2 O stands for di-tert-butyl dicarbonate
- NMM stands for N-methylmorpholine.
- the reaction solution was depressurized -0.095Mpa and rotary steamed at 50°C.
- the mixture of ethanol and water (9.2L) was distilled out, and ethyl acetate was added to the concentrated solution.
- Dissolve compound 3 (1562.30 g, 7.189 mol) in dichloromethane (4.0 liters), add dropwise for 1 hour at -30 ⁇ -20°C, control the temperature at -30 ⁇ -20°C, stir and react for 2 hours, Slowly rise to room temperature and react for 14 hours. TLC control detects that the reaction is complete.
- the reaction was quenched by adding water (6.0 L) at room temperature, and then extracted with dichloromethane (2.0 L*2), the organic layer was washed with saturated sodium chloride (4.0 L), and then dried with anhydrous sodium sulfate (1.0 kg). Filter, collect the mother liquor, reduce pressure -0.090Mpa, and rotate at 40°C to obtain concentrated liquid oil (1860.00 g).
- the reaction solution was filtered with diatomaceous earth, the filter cake was washed with ethyl acetate (10.0 liters), the mother liquor was collected, layered, and the upper organic layer was separated and used 10% thiosulfuric acid Sodium aqueous solution (10.0L), stirred for 0.5 hours, separated, the organic phase was washed with saturated brine (10.0L*8), separated, the organic phase was dried with anhydrous sodium sulfate (1000.0g), filtered, the mother liquor was collected and subtracted Press -0.095Mpa, rotate and evaporate at 50°C, remove the solvent, and obtain a crude product (1322.0 g) as a white solid.
- the concentrated solution was diluted with water (15.0 liters), extracted with ethyl acetate (15.0 liters), separated, the ethyl acetate layer was washed with saturated brine (10.0 liters), separated, and the organic phase was washed with anhydrous sodium sulfate (2.0 kg) dried, filtered, collected the mother liquor, reduced pressure -0.095Mpa, and rotary evaporated at 50°C to obtain compound 8 (7373.15 g, yield 97.43%, purity 97.378%) as a brown oil.
- the concentrate was dissolved in methanol (10.5 liters), 2M potassium hydroxide (10.5 liters) was added, and the temperature was controlled at 30-40° C. and the reaction was stirred for 1 hour.
- the reaction was detected to be complete by HPLC.
- Extraction, liquid separation save the water layer, wash the isopropyl acetate layer with 4M potassium hydroxide (5.0 L), and combine the water phases.
- the oil pump depressurizes -0.095Mpa, the bath temperature is controlled at 20-30°C, and the solvent is removed by rotary evaporation to constant weight to obtain a yellow solid compound. 11 (1856.04 g, yield 62.20%, purity 93.750%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (12)
- 一种式(I)化合物的制备方法,其特征在于,包含如下步骤:其中,W选自OH、C 1-6烷氧基和C 1-6烷氨基;R 1选自C 1-6烷基;R 2选自H、F、Cl、Br、I、CN、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、-C(=O)-C 1-6烷基、C 3-6环烷基和3-6元杂环烷基,所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基和3-6元杂环烷基任选被1、2或3个R a取代;R选自H、OH、CN、NH 2、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷硫基、-C(=O)-C 1-6烷基、-C(=O)-C 1-6烷氨基、-O-C(=O)-C 1-6烷氨基、-NH-C(=O)-C 1-6烷氧基、C 2-5烯基、C 2-5杂烯基、C 3-6环烷基和3-6元杂环烷基,所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷硫基、-C(=O)-C 1-6烷基、-C(=O)-C 1-6烷氨基、-O-C(=O)-C 1-6烷氨基、-NH-C(=O)-C 1-6烷氧基、 C 2-5烯基、C 2-5杂烯基、C 3-6环烷基和3-6元杂环烷基任选被1、2或3个R b取代;m选自0、1、2、3、4和5;R a和R b分别独立地选自COOH、F、Cl、Br、I、OH、CN、NH 2、CH 3、CH 2CH 3、CH 2CH 2CH 3、OCH 3、-NHCH 3、-N(CH 3) 2和CF 3。
- 如权利要求1所述的制备方法,其中,R选自H、OH、CN、NH 2、C 1-3烷基、C 1-3烷氧基、C 1-3烷氨基、C 1-3烷硫基、-C(=O)-C 1-3烷基、-C(=O)-C 1-3烷氨基、-O-C(=O)-C 1-3烷氨基、-NH-C(=O)-C 1-3烷氧基、C 2-3烯基、C 2-3杂烯基、C 3-6环烷基和3-6元杂环烷基,所述C 1-3烷基、C 1-3烷氧基、C 1-3烷氨基、C 1-3烷硫基、-C(=O)-C 1-3烷基、-C(=O)-C 1-3烷氨基、-O-C(=O)-C 1-3烷氨基、-NH-C(=O)-C 1-3烷氧基、C 2-3烯基、C 2-3杂烯基、C 3-6环烷基和3-6元杂环烷基任选被1、2或3个R b取代。
- 如权利要求1-3任意一项所述的制备方法,其中,W选自OH、-OCH 2CH 3和-N(CH 3) 2。
- 如权利要求1-3任意一项所述的制备方法,其中,R 2选自H、F、Cl、Br、I、CN、C 1-3烷基、C 1-3烷氧基、C 1-3烷氨基、-C(=O)-C 1-3烷基、C 3-6环烷基和3-6元杂环烷基,所述C 1-3烷基、C 1-3烷氧基、C 1-3烷氨基、-C(=O)-C 1-3烷基、C 3-6环烷基和3-6元杂环烷基任选被1、2或3个R a取代。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/635,462 US20220306648A1 (en) | 2019-08-15 | 2020-07-28 | Preparation Method for Oxazepine Compound |
JP2022509613A JP7433415B2 (ja) | 2019-08-15 | 2020-07-28 | オキサゼピン系化合物の調製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910754972 | 2019-08-15 | ||
CN201910754972.2 | 2019-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021027566A1 true WO2021027566A1 (zh) | 2021-02-18 |
Family
ID=74570502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/105248 WO2021027566A1 (zh) | 2019-08-15 | 2020-07-28 | 氧氮杂卓类化合物的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220306648A1 (zh) |
JP (1) | JP7433415B2 (zh) |
CN (1) | CN112390816B (zh) |
TW (1) | TWI746110B (zh) |
WO (1) | WO2021027566A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11964986B1 (en) | 2023-07-03 | 2024-04-23 | Rejuveron Telomere Therapeutics Ag | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849037A (zh) * | 2015-07-21 | 2018-03-27 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新的三环4‑吡啶酮‑3‑甲酸衍生物 |
CN108884107A (zh) * | 2017-05-22 | 2018-11-23 | 福建广生堂药业股份有限公司 | 乙型肝炎病毒表面抗原抑制剂 |
CN109715624A (zh) * | 2016-07-29 | 2019-05-03 | 新波制药有限公司 | 用于治疗hbv感染的新颖治疗剂 |
CN110114071A (zh) * | 2016-11-07 | 2019-08-09 | 爱彼特生物制药公司 | 含有取代的吡啶酮的三环化合物以及使用其的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2867221B1 (en) | 2012-06-28 | 2018-01-17 | AbbVie Inc. | Cyanoguanidines and their sue as antiviral agents. |
WO2016206101A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
PT3587420T (pt) * | 2017-02-23 | 2021-06-04 | Fujian Cosunter Pharmaceutical Co Ltd | Composto tricíclico e suas aplicações |
US20200197409A1 (en) | 2017-05-22 | 2020-06-25 | Fujian Cosunter Pharmaceutical Co., Ltd. | Hepatitis b virus surface antigen inhibitor |
-
2020
- 2020-07-28 CN CN202010737285.2A patent/CN112390816B/zh active Active
- 2020-07-28 WO PCT/CN2020/105248 patent/WO2021027566A1/zh active Application Filing
- 2020-07-28 JP JP2022509613A patent/JP7433415B2/ja active Active
- 2020-07-28 US US17/635,462 patent/US20220306648A1/en active Pending
- 2020-08-13 TW TW109127491A patent/TWI746110B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849037A (zh) * | 2015-07-21 | 2018-03-27 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新的三环4‑吡啶酮‑3‑甲酸衍生物 |
CN109715624A (zh) * | 2016-07-29 | 2019-05-03 | 新波制药有限公司 | 用于治疗hbv感染的新颖治疗剂 |
CN110114071A (zh) * | 2016-11-07 | 2019-08-09 | 爱彼特生物制药公司 | 含有取代的吡啶酮的三环化合物以及使用其的方法 |
CN108884107A (zh) * | 2017-05-22 | 2018-11-23 | 福建广生堂药业股份有限公司 | 乙型肝炎病毒表面抗原抑制剂 |
Non-Patent Citations (1)
Title |
---|
HAGHSHENAS POUYAN, GRAVEL MICHEL: "Chemo- and Diastereoselective N -Heterocyclic Carbene-Catalyzed Cross-Benzoin Reactions Using N -Boc-α-amino Aldehydes", ORGANIC LETTERS, vol. 18, no. 18, 16 September 2016 (2016-09-16), American Chemical Society, US, pages 4518 - 4521, XP055780536, ISSN: 1523-7060, DOI: 10.1021/acs.orglett.6b02123 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11964986B1 (en) | 2023-07-03 | 2024-04-23 | Rejuveron Telomere Therapeutics Ag | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives |
Also Published As
Publication number | Publication date |
---|---|
TWI746110B (zh) | 2021-11-11 |
US20220306648A1 (en) | 2022-09-29 |
CN112390816A (zh) | 2021-02-23 |
JP2022544316A (ja) | 2022-10-17 |
CN112390816B (zh) | 2023-05-26 |
JP7433415B2 (ja) | 2024-02-19 |
TW202115004A (zh) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113194958B (zh) | THRβ受体激动剂化合物及其制备方法和用途 | |
CN102766138B (zh) | 一种阿齐沙坦的制备方法 | |
EP0307303B1 (fr) | [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique | |
JP2724114B2 (ja) | トリテルペン誘導体およびそれを含有するエンドセリンレセプター拮抗剤 | |
EP0435749B1 (fr) | Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
CN105712984A (zh) | 一种阿齐沙坦的制备方法 | |
CN112079848A (zh) | 巴洛沙韦关键中间体的合成方法 | |
CN102351778A (zh) | 一种盐酸阿比朵尔的制备方法 | |
JP5972986B2 (ja) | Cddoエチルエステルの多形体及びその用途 | |
WO2011116490A1 (zh) | 制备消旋卡多曲的方法 | |
WO2021027566A1 (zh) | 氧氮杂卓类化合物的制备方法 | |
JPS63230689A (ja) | ベンゾオキサジン誘導体 | |
JPS6399057A (ja) | グリシン誘導体 | |
CN103694178A (zh) | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 | |
JP7244487B2 (ja) | ステロイド系誘導体fxrアゴニストの結晶又は非晶質、その製造方法及び使用 | |
CN106279018B (zh) | β2-受体***及其制备方法和应用 | |
WO2021110135A1 (zh) | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 | |
CN104387332B (zh) | 一种合成芳香化酶抑制剂的方法 | |
EP0136198A1 (fr) | Dérivés de triazolo pyrimidine, leur procédé de préparation et leur application thérapeutique en tant que toni-cardiaques | |
WO2021110138A1 (zh) | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 | |
CN114853736B (zh) | 具有trk抑制活性的化合物、制备方法、组合物及其用途 | |
CN115124473B (zh) | 西咪替丁有关物质b的合成方法 | |
WO2024087782A1 (zh) | 一种gpr139受体激动剂、其制备方法及其应用 | |
CN103772308B (zh) | 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法 | |
JPS6141915B2 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20852622 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022509613 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20852622 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20852622 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/10/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20852622 Country of ref document: EP Kind code of ref document: A1 |